Pembrolizumab Plus Chemotherapy to Combat Breast Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：561 / 561
页数：1
相关论文
共 50 条
  • [41] A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer
    Isono, Taisuke
    Kagiyama, Naho
    Shibata, Shun
    Nakajima, Hitomi
    Matsui, Yuma
    Takano, Kenji
    Nishida, Takashi
    Hosoda, Chiaki
    Kawate, Eriko
    Kobayashi, Yoichi
    Ishiguro, Takashi
    Takaku, Yotaro
    Kurashima, Kazuyoshi
    Yanagisawa, Tsutomu
    Takayanagi, Noboru
    THORACIC CANCER, 2021, 12 (09) : 1387 - 1397
  • [42] Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial
    Matsumoto, Hiromi
    Kobayashi, Nobuaki
    Somekawa, Kohei
    Fukuda, Nobuhiko
    Kaneko, Ayami
    Kamimaki, Chisato
    Kubo, Sousuke
    Tanaka, Katsushi
    Tagami, Yoichi
    Teranishi, Shuhei
    Watanabe, Keisuke
    Horita, Nobuyuki
    Hara, Yu
    Yamamoto, Masaki
    Kudo, Makoto
    Koizumi, Harumi
    Miura, Kenji
    Miyazawa, Naoki
    Kaneko, Takeshi
    THORACIC CANCER, 2022, 13 (02) : 228 - 235
  • [43] Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer
    Saeki T.
    Takashima S.
    Breast Cancer, 2004, 11 (2) : 116 - 120
  • [44] Neoadjuvant immunochemotherapy of pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
    Chen, Y.
    Yan, B.
    You, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S108 - S109
  • [45] Pembrolizumab in the Treatment of Breast Cancer
    Pivot, Xavier
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03): : 273 - 274
  • [46] BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
    Bockorny, Bruno
    Semenisty, Valerya
    Macarulla, Teresa
    Borazanci, Erkut
    Wolpin, Brian M.
    Stemmer, Salomon M.
    Golan, Talia
    Geva, Ravit
    Borad, Mitesh J.
    Pedersen, Katrina S.
    Park, Joon Oh
    Ramirez, Robert A.
    Abad, David G.
    Feliu, Jaime
    Munoz, Andres
    Ponz-Sarvise, Mariano
    Peled, Amnon
    Lustig, Tzipora M.
    Bohana-Kashtan, Osnat
    Shaw, Stephen M.
    Sorani, Ella
    Chaney, Marya
    Kadosh, Shaul
    Haras, Abi Vainstein
    Von Hoff, Daniel D.
    Hidalgo, Manuel
    NATURE MEDICINE, 2020, 26 (06) : 878 - +
  • [47] BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
    Bruno Bockorny
    Valerya Semenisty
    Teresa Macarulla
    Erkut Borazanci
    Brian M. Wolpin
    Salomon M. Stemmer
    Talia Golan
    Ravit Geva
    Mitesh J. Borad
    Katrina S. Pedersen
    Joon Oh Park
    Robert A. Ramirez
    David G. Abad
    Jaime Feliu
    Andres Muñoz
    Mariano Ponz-Sarvise
    Amnon Peled
    Tzipora M. Lustig
    Osnat Bohana-Kashtan
    Stephen M. Shaw
    Ella Sorani
    Marya Chaney
    Shaul Kadosh
    Abi Vainstein Haras
    Daniel D. Von Hoff
    Manuel Hidalgo
    Nature Medicine, 2020, 26 : 878 - 885
  • [48] Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
    Chen, Yulong
    Yan, Bo
    Zhang, Ran
    Zhao, Gang
    You, Jian
    HELIYON, 2023, 9 (09)
  • [49] Pembrolizumab/ Sacituzumab Govitecan Does Not Statistically Improve PFS in HR plus Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2024, 38 (07):
  • [50] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis
    Cortes, J.
    Haiderali, A.
    Huang, M.
    Pan, W.
    Fox, G. E.
    Park, J.
    Frederickson, A. M.
    Fasching, P. A.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S615 - S616
12345